Radiopharm Theranostics Limited (RADX)

Market Cap	39.75M
Revenue (ttm)	8.20M
Net Income (ttm)	-25.14M
Shares Out	2.36B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,106
Open	4.240
Previous Close	4.300
Day's Range	4.200 - 4.620
52-Week Range	3.496 - 50.820
Beta	0.90
Analysts	Strong Buy
Price Target	15.00 (+231.86%)
Earnings Date	n/a

About RADX

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: RADX

Financial Performance

In 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.

Financial numbers in AUD

Analyst Summary

According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 231.86% from the latest price.

Price Target

$15.0

(231.86% upside)

Analyst Consensus: Strong Buy